Divergent shifts in lipid mediator profile following supplementation with n‐3 docosapentaenoic acid and eicosapentaenoic acid
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
In contrast to the well‐characterized effects of specialized proresolving lipid mediators (SPMs) derived fromeicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), little is known about themetabolic fate of the intermediary long‐chain (LC) n‐3 polyunsaturated fatty acid (PUFA) docosapentaenoic acid (DPA). In this double blind crossover study, shifts in circulating levels of n‐3 and n‐6 PUFA‐derived bioactive lipid mediators were quantified by an unbiased liquid chromatography‐tandem mass spectrometry lipidomic approach. Plasma was obtainedfrom humansubjects before andafter 7 d of supplementationwith pure n‐3DPA, n‐3 EPA or placebo (olive oil). DPA supplementation increased the SPM resolvin D5 n‐3DPA (RvD5 n‐3DPA ) and maresin (MaR)‐1, the DHA vicinal diol 19, 20‐dihydroxy‐DPA and n‐6 PUFA derived 15‐keto‐PG E 2 (15‐keto‐PGE 2 ). EPA supplementation had no effect on any plasma DPA or DHA derived mediators, but markedly elevated monohydroxy‐eicosapentaenoic acids (HEPEs), including the e ‐series resolvin (RvE) precursor 18‐HEPE; effects not observed with DPA supplementation. These data show that dietary n‐3 DPA and EPA have highly divergent effects on human lipid mediator profile, with no overlap in PUFA metabolites formed. The recently uncovered biologic activity of n‐3 DPA docosanoids and their marked modulation by dietary DPA intake reveals a unique and specific role of n‐3 DPA in human physiology.—Markworth, J. F., Kaur, G., Miller, E.G., Larsen, A. E., Sinclair, A. J., Maddipati, K.R., Cameron‐Smith, D. Divergent shifts in lipid mediator profile following supplementation with n‐3 docosapentaenoic acid and eicosapentaenoic acid. FASEB J. 30, 3714–3725 (2016) www.fasebj.org
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
The Opposing Effects of N-3 and n-6 Fatty Acids
Schmitz, G., & Ecker, J. (2008) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.12.004 · Cited by 1,245 · cited 1×
“ute to anti-inflammatory LC n-3 PUFA bioactivity (6).”
BackgroundSerhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189 · cited 2×
“Similarly, EPA is converted to 18R-hydroxy-EPA (18R-HEPE) by acetylated COX-2 (in the presence of aspirin) (16) or endogenous cytochromeP450 (in the absence of aspirin) (17).”
BackgroundHong, S., Gronert, K., Devchand, P. R., Moussignac, R.-L., & Serhan, C. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300218200 · Cited by 1,000
Maresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081880 · Cited by 908 · cited 11×
“In the present study, we detected several DHA-derived SPMs at low pictogram permilliliter concentrations in human plasma, including RvD1, RvD2, RvD6,MaR1, and 10S,17S-DiHDoHE (PD1 isomer or PDX).”
BackgroundInfluentialMarcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J. M., Chiang, N., Serhan, C. N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305841200 · Cited by 802 · cited 1×
“These analytes included metabolites of linoleic acid (LA) (18:2, n-6) encompassing both hydroxy-/ oxo-octadecadienoic acids (9-HODE/9-OxoODE, 13HODE/13-OxoODE)andepoxy-/dihydroxy-octadecanoic acids [9(10)EpOME/9(10)DiHOME, 12(13)EpOME/12 (13)DiHOME], all of which decreased by ;30–60% from d 0 to 7 of the initial OO tr…”
BackgroundMukherjee, P. K., Marcheselli, V. L., Serhan, C. N., & Bazan, N. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402531101 · Cited by 753 · cited 1×
“For example, metabolism of DHA via 15-LOX and 12-LOX pathways generates 17S-HpDoHE and 14S-HpDoHE, key intermediates in the PD (9) and MaR (10, 11) biosynthetic pathways, respectively.”
Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins
Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., & Serhan, C. N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4345 · Cited by 699
Docosapentaenoic acid (22:5n-3): A review of its biological effects
Kaur, G., Cameron-Smith, D., Garg, M., & Sinclair, A. J. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.07.004 · Cited by 337 · cited 1×
“Compared with EPA and DHA, very little is known regarding the metabolic fate and bioactivity of the third intermediary dietary n-3 PUFA DPA (22:5, n-3) (29, 30).”
Background
Cited by
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Serhan, C. N., & Levy, B. D. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97943 · Cited by 1,344
“These n-3 immunoresolvents are biosynthesized (Figure 2) in three families: resolvin n-3DPA , protectin n-3DPA , and maresin n-3DPA , each demonstrating potent pro-resolving actions (27) in human subjects (78).”
BackgroundDyall, S. C., Balas, L., Bazan, N. G., Brenna, J. T., Chiang, N., da Costa Souza, F., Dalli, J., Durand, T., Galano, J.-M., Lein, P. J., et al. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101165 · Cited by 660
Layé, S., Nadjar, A., Joffre, C., & Bazinet, R. P. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014092 · Cited by 420
“…a lipidomic approach, Ibuprofen (a nonselective inhibitor of COX) was shown to block exerciseinduced increase in prostanoids and leukotrienes, but also anti-inflammatory/proresolving lipid mediators, possibly explaining the mitigated beneficial effect of COX inhibitors (Markworth et al., 2016).”
BackgroundMethodInfluentialDrouin, G., Rioux, V., & Legrand, P. (2019) · Biochimie · doi:10.1016/j.biochi.2019.01.022 · Cited by 164
Dalli, J., & Serhan, C. N. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14336 · Cited by 138
“While the evidence in humans for the utility of this approach is still being investigated, results from animal and initial human experiments are encouraging (Dalli et al., 2013; Arnardottir et al., 2016; Barden et al., 2016; Markworth et al., 2016; Gobbetti et al., 2017).”
BackgroundResult
Metadata
- Authors
- Markworth, J. F., Kaur, G., Miller, E. G., Larsen, A. E., Sinclair, A. J., Rao Maddipati, K., & Cameron‐Smith, D.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2016-07-26
- Volume
- 30
- Issue
- 11
- Pages
- 3714-3725
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2489594338
- Cited by
- 89
- References
- 12
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Divergent shifts in lipid mediator profile following supplementation with n‐3 docosapentaenoic acid and eicosapentaenoic acid. https://app.cochat.ai/papers/10.1096/fj.201600360r
- The paper
- Markworth, J. F., Kaur, G., Miller, E. G., Larsen, A. E., Sinclair, A. J., Rao Maddipati, K., & Cameron‐Smith, D. (2016). Divergent shifts in lipid mediator profile following supplementation with n‐3 docosapentaenoic acid and eicosapentaenoic acid. The FASEB Journal. https://doi.org/10.1096/fj.201600360r
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.